Vitreous disorder

Summary

Vitreous disorder (MONDO:0004860) is a disease and 6 clinical trials. A subtype of vitreous body disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vitreous disorder
Mondo ID	MONDO:0004860
DOID	DOID:9720
UMLS	C0700141
MedGen	1843447
Anatomy (UBERON)	UBERON:0001797
Is cancer (heuristic)	no

Also known as: disease of vitreous humor · disease of vitreous humour · disease or disorder of vitreous humor · disease or disorder of vitreous humour · disorder of vitreous humor · disorder of vitreous humour · vitreous humor disease · vitreous humor disease or disorder · vitreous humour disease · vitreous humour disease or disorder

Disease family

This is a subtype of vitreous body disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › vitreous body disorder › vitreous disorder

Related subtypes (1): hyalitis

Subtypes (4): vitreous syneresis, vitreous abscess, vitreous detachment, persistent hyperplastic primary vitreous

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06520410	PHASE4	RECRUITING	Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries
NCT04570007	Not specified	UNKNOWN	Vitreous Fragments Length After Pars Plana Vitrectomy
NCT05229094	Not specified	COMPLETED	EVA Nexus Vitrectomy Device Field Observation Study
NCT05427526	Not specified	COMPLETED	Outcome of Zeiss AT LARA EDOF Lens Implantation in Vitrectomized Eyes
NCT05583331	Not specified	COMPLETED	Comparison of Two Surgical Sequences Cataract Surgery Then Vitrectomy Versus Vitrectomy Then Cataract Surgery Under Local-regional Anesthesia
NCT06160960	Not specified	UNKNOWN	Influence of Pupillary Behavior During Eye Surgery on Morphological and Functional Outcome